 Duration of the study The study duration is 18 months for enrollment and 2 years for the follow-up. Efficacy Assessments Treatment response will be assessed by tumor imaging spiral CT of neck, chest, abdomen, pelvis and PET scans performed at protocol-specified timepoints. Determination of antitumor efficacy will be based on objective response assessments made according to the Revised Response Criteria for Malignant Lymphoma. Clinical response of progressive disease PD, stable disease SD, partial remission PR, or complete remission CR will be determined at each assessment. Responses will be determined by investigator. 